ACADIA announces robust, consistant efficacy of pimavanserin ACADIA presented detailed results from ACADIA's pivotal Phase III -020 Study with pimavanserin in patients with Parkinson's disease psychosis. The analysis of the full data set from the Phase III -020 Study showed robust and consistent efficacy of pimavanserin across a wide array of study measures and confirmed the positive top-line results previously reported. Pimavanserin met the primary endpoint in the -020 Study by demonstrating highly significant antipsychotic efficacy on the 9-item SAPS-PD scale. Pimavanserin also met the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinson's Disease Rating Scale, or UPDRS.
News For ACAD From The Last 14 Days
Check below for free stories on ACAD the last two weeks.
Subscribe for More Information